November 20, 2025
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition Download this news article Read More Read MoreOctober 15, 2025
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome Download this news article Read More Read MoreAugust 17, 2025
Pioneering therapy could halt rigours of ageing Download this news article Read More Read MoreJuly 24, 2025
Minovia Therapeutics Announces Interim Data from Phase 2 Trial Download this news article Read More Read MoreJune 30, 2025
Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome Download this news article Read More Read MoreJune 25, 2025
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Download this news article Read More Read MoreApril 3, 2025
Minovia Therapeutics Announces FDA Clearance of Second IND Download this news article Read More Read MoreSeptember 26, 2024
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome Download this news article Read More Read MoreJanuary 5, 2023
Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member Download this news article Read More Read MoreJanuary 3, 2023
Minovia Therapeutics to Present at Biotech Showcase on J.P. Morgan Healthcare week Download this news article Read More Read More